Тяжёлый острый респираторный синдром: новые фрагменты головоломки | КМАХ

Тяжёлый острый респираторный синдром: новые фрагменты головоломки

Клиническая Микробиология и Антимикробная Химиотерапия. 2004; 6(2):108-123

​ Синопальников А.И., Воробьев А.В.
ТОРС вирусная инфекция эпидемиология эпидемия
Раздел
Болезни и возбудители
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2004; 6(2):108-123

Аннотация

Тяжёлый острый респираторный синдром (ТОРС) - новое высококонтагиозное респираторное заболевание вирусной этиологии, впервые появившееся в ноябре 2002 года на территории провинции Гуандун на юге Китая и стремительно распространившееся по территории 29 государств Европы, Азии, Северной и Южной Америки и Австралии. Ценой экстраординарных усилий мирового сообщества пандемия была остановлена, однако спустя нескольким более 5 месяцев было сообщено о новых случаях ТОРС с неустановленным источником инфицирования. В данной статье содержатся дополненные с учётом современных представлений данные о заболевании.

  • 1. http://www.who.int/csr/don/2003_03_19/en/
  • 2. h t t p : / / w w w . c d c . g o v / o d / o c / m e d i a / p r e s s r e l / r 030324.htm/
  • 3. Peiris J.S., Lai S.T., Poon L.L., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319-25.
  • 4. Philip P. Pan New SARS case confirmed. Washington Post Foreign Service; Tuesday, Jan 6, 2004; A11.
  • 5. El-Sahly H.M., Atmar R.L., Glezen W.P., Greenberg S.B. Spectrum of clinical illness in hospitalized patients with «common cold» virus infections. Clin Infect Dis 2000; 31:96-100.
  • 6. Folz R.J., Elkordy M.A. Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer. Chest 1999; 115: 901-5.
  • 7. Marra M.A., Jones S.J., Astell K.R., et al. The genome sequence of the SARS-associated coronavirus. Science 2003; 300: 1399-404.
  • 8. Snijder E.J., Bredenbeek P.J., Dobbe J.C., et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 2003; 331: 991-1004.
  • 9. Gay N., Ma S. Presentation on the modelling of data from Singapore. Global Meeting on the Epidemiology of SARS World Health Organization; Geneva, Switzerland; 16-17 May 2003.
  • 10. http://www.who.int/csr/sars/archive/epiconsensus/en/
  • 11. Riley S. Fraser C., Donnelly C.A., et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science 2003; 300: 1961-66.
  • 12. Cyranoski D., Abbott A. Virus detectives seek source of SARS in China’s wild animals. Nature 2003; 423: 467-8.
  • 13. http://www.who.int/csr/sars/survival_2003_05_04/en/index.html.
  • 14. Lee N., Hui D., Wu A., et al. A Major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1986-94.
  • 15. Peiris J.S., Chu C.M., Cheng V.C., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767-72.
  • 16. Donnelly C.A., Ghani A.C., Leung G.M., et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003; 361: 1761-6.
  • 17. Booth C.M., Matukas L.M., Tomlinson G.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289: 2801-9.
  • 18. Wong R., Wu A., To K.F., et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003; 326: 1358-62.
  • 19. Tsang K.W. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1977-85.
  • 20. Poutanen S.M., Low D.L., Henry B., et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348 :1995-2005.
  • 21. Wong K.T. Severe Acute Respiratory Syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 2003; 228: 401-13.
  • 22. Rainer T.H., Cameron P.A., DeVilliers S., et al. Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study. BMJ 2003; 326: 1354-8.
  • 23. Wong K.T., Antonio G.E., Hui D.S.C. Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology 2003; 228: 395.
  • 24. http://www.sarsreference.com/index.htm
  • 25. http://www15.bni-hamburg.de/bni/bni2/neu2/
  • 26. http://www.who.int/csr/resources/publications/biosafety/labbiosafety.pdf
  • 27. http://www.who.int/csr/sars/casedefinition/en/
  • 28. So L.K.Y., Lau A.C., Yam L.Y., et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003; 361: 1615-6.
  • 29. Dalhoff A., Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003; 3: 359-71.
  • 30. Labro M.T., Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001; 13: 3-8.
  • 31. Cinatl J., Morgenstern B., Bauer G., et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003; 361: 2045-6.
  • 32. Van Vonderen M.G.A. Ribavirin in the treatment of severe acute respiratory syndrome (SARS). Neth J Med 2003; 61: 238-42.
  • 33. Ning Q., Brown D., Parodo J., et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160: 3487-93.
  • 34. Hultgren C., Milich D.R., Weiland O. The antiviral compound ribavirin modulates the T-helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79: 2381-91.
  • 35. Chan K.S., Lai S.T., Chu C.M. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003; 9: 399-406.
  • 36. Zhao Z., Zhang F., Xu M. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003; 52: 715-20.
  • 37. Wu W., Wang J., Liu P., et al. A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China. Chin Med J 2003;116:811-8.
  • 38. Bob Roehr Alfacon-1 Plus Steroids Leads to Rapid Improvement in SARS Available from: http://www.medscape.com
  • 39. Cinatl J., Morgenstern B., Bauer G., et al. Treatment of SARS with human interferons. Lancet 2003; 362: 293-4.
  • 40. Wong V.W., Dai D., Wu A.K., et al. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003; 9: 199-201.
  • 41. Lin L., Han Y., Yang Z.M. Clinical observation on 103 patients with severe acute respiratory syndrome treated by integrative traditional Chinese and western medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 2003; 23: 409-13.
  • 42. Xiao Z.L., Li Y.M., Chen R.C., et al. A retrospective study of 78 patients with severe acute respiratory syndrome. Chin Med J 2003; 116: 805-10.
  • 43. Badam L. In vitro antiviral activity of indigenous glycyrrhizin, licorice and glycyrrhizic acid (Sigma) on Japanese encephalitis virus. J Commun Dis 1997; 29: 91-9.
  • 44. Baba M., Shigeta S. Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro. Antiviral Res 1987; 7: 99-107.
  • 45. Ito M., Nakashima H. Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus. Antiviral Res 1987; 7: 127-37.
  • 46. Nakashima H., Matsui T. A new anti-human immunodeficiency virus substance, glycyrrhizin sulfate: endowment of glycyrrhizin with reverse transcriptase-inhibitory activity by chemical modification. Jpn J Cancer Res 1987; 78: 767-71.
  • 47. Hattori T., Kematsu S. Preliminary evidence for inhibitory effects of glycyrrhizin on HIV replication in patients with AIDS. Antiviral Res 1989; 11; 255-61.
  • 48. Takahara T., Watanabe A. Effects of glycyrrhizin on hepatitis B surface antigen: a biochemical and morphological study. J Hepatol 1994; 21; 6019.
  • 49. Abe Y., Ueda T. Effectiveness of interferon glycyrrhizin combination therapy in patients with chronic hepatitis C. Nippon Rinsho 1994; 52: 181722.
  • 50. Cinatl J., Morgenstern B., Bauer G., et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003; 361: 2045-6.
  • 51. Xiao Z.L., Li Y.M., Chen R.C., et al. A retrospective study of 78 patients with severe acute respiratory syndrome. Chin Med J 2003; 116: 805-10.
  • 52. Ho J.C., Ooi G.C., Mok T.Y., et al. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003; 168:1449-56.
  • 53. Yao W., Chen Y., Zhang L., et al. Chest X-ray changes after discontinuation of glucocorticoids treatment on severe acute respiratory syndrome (5 cases report). Beijing Da Xue Xue Bao 2003; 35 (Suppl): 26-8.
  • 54. http://www.china.org.cn/english/scitech/78957.htm
  • 55. Martin J.F., Jimenez J.L., Munoz-Fernandez A. Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. Med Sci Monit 2003; 9:29-34.
  • 56. So L.K.Y., Lau A.C.W., Yam L.Y.C., et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003; 361: 1615-6.
  • 57. De Groot A.S. How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past. Vaccine 2003; 21: 4095-104.
  • 58. http://www.who.int/mediacentre/releases/2003/pr83/en/
  • 59. http://www.cdc.gov/ncidod/sars/sarsprepplan.htm
  • 60. www.sciencemag.org/cgi/content/abstract/303/5664/1666
  • 61. Ruder K. SARS may still be jumping from animals to people. GNN News Article. Available from: http://www.genomenewsnetwork.com/articles/2004/01/29
  • 62. http://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/
  • 63. Dongping X., Zheng Z., Fuliang C. Genetic Variation of SARS Coronavirus in Beijing Hospital. Emerg Infect Dis 2004, 10: 789-94.
  • 64. Ding Y., He L., Zhang Q. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol 2004; 203:622-30.
  • 65. http://www3.interscience.wiley.com/cgi-bin/abstract/108562761/ABSTRACT
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились